Get the Stockscreener App
13.42
1.44%
0.19
Polyrizon Ltd stock is traded at $13.42, with a volume of 66,730.
It is up +1.44% in the last 24 hours and down -2.12% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$13.23
Open:
$13.52
24h Volume:
66,730
Relative Volume:
1.53
Market Cap:
$27.97M
Revenue:
-
Net Income/Loss:
$-3.34M
P/E Ratio:
-4.9713
EPS:
-2.6995
Net Cash Flow:
$-10.54M
1W Performance:
+15.89%
1M Performance:
-2.12%
6M Performance:
+32.74%
1Y Performance:
+195.00%
1-Day Range:
$12.50
$13.52
1-Week Range:
$10.37
$13.52
52-Week Range:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
13.42 | 27.97M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polyrizon Ltd Stock (PLRZ) Latest News
Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polyrizon Ltd (PLRZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Polyrizon Announces U.S. Publication of Mucoadhesive Nasal Drug Delivery Patent - TipRanks
Polyrizon (Nasdaq: PLRZ) details U.S. patent publication for Trap & Target nasal platform - Stock Titan
Polyrizon announces U.S. patent application publication - Investing.com
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform - The Manila Times
Polyrizon patent published for nasal drug-delivery technology - Stock Titan
Polyrizon Ltd (PLRZ) Institutional Confidence - TradingKey
Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polyrizon Ltd (PLRZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Polyrizon Ltd (PLRZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polyrizon Launches Key Human Study to Advance NASARIX Allergy Blocker Toward FDA Pathway - TipRanks
Polyrizon (PLRZ) launches NASARIX™ human study to assess nasal residence and aid FDA path - Stock Titan
Polyrizon stock surges on human study for allergy blocker By Investing.com - Investing.com South Africa
Polyrizon stock surges on human study for allergy blocker - Investing.com
Polyrizon Ltd. Enters Agreement With European University Medical Center And Clinical Research Organization For Human Study Of NASARIX? - marketscreener.com
Polyrizon initiates nasal residence time study for allergy blocker - Investing.com
Polyrizon initiates nasal residence time study for allergy blocker By Investing.com - Investing.com Canada
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway - The Manila Times
How long can a nasal allergy blocker stay put? New human study aims to find out - Stock Titan
Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polyrizon Wins European Patent Publication for Mucoadhesive Nasal Drug Delivery Platform - TipRanks
Polyrizon (Nasdaq: PLRZ) moves ahead on European nasal drug patent - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon Marches on European Patent - Baystreet.ca
Polyrizon receives European patent application publication - Investing.com
Polyrizon receives European patent application publication By Investing.com - Investing.com South Africa
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology - The Manila Times
Polyrizon Ltd. Announces Publication of European Patent Application for Innovative Nasal Drug Delivery Technology - Quiver Quantitative
Polyrizon Sets July 13, 2026 AGM to Vote on Board, Pay and Auditor Mandates - The Globe and Mail
Polyrizon schedules annual shareholder meeting for July 13 By Investing.com - Investing.com Canada
Polyrizon Secures Three Key U.S. Sites for NASARIX Allergy Trial - TipRanks
Polyrizon schedules annual shareholder meeting for July 13 - Investing.com
Polyrizon (PLRZ) 2026 AGM to vote on compensation policy, major RSU grants and Deloitte re-appointment - Stock Titan
Polyrizon (Nasdaq: PLRZ) signs 3 key U.S. sites for NASARIX allergy trial - Stock Titan
Polyrizon signs two more U.S. sites for allergy trial By Investing.com - Investing.com South Africa
Polyrizon signs two more U.S. sites for allergy trial - Investing.com
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial - The Manila Times
Polyrizon Ltd. Expands Clinical Trial Network for NASARIX™ Allergy Blocker with Two New U.S. Sites - Quiver Quantitative
New nasal gel trial to block airborne seasonal allergens in U.S. - Stock Titan
Polyrizon extends exclusivity for 51% Arrow Aviation acquisition - scanx.trade
Polyrizon extends exclusivity period for Arrow Aviation acquisition talks By Investing.com - Investing.com Nigeria
Polyrizon Extends Exclusivity on Proposed 51% Acquisition of Arrow Aviation - TipRanks
Polyrizon extends exclusivity period for Arrow Aviation acquisition talks - Investing.com
Polyrizon (NASDAQ: PLRZ) prolongs Arrow Aviation 51% stake talks - Stock Titan
Polyrizon Shares Flat After Delay in New Filing Near Highs - Bez Kabli
Polyrizon Appoints Veteran Entrepreneur Ami Oren to Board of Directors - The Globe and Mail
Polyrizon Ltd. (PLRZ) Posts Modest Gain as Stock Consolidates Near Support LevelsETH Profile - The Legal Advocate
Polyrizon (PLRZ) appoints entrepreneur Ami Oren as new Class I director - Stock Titan
Polyrizon Ltd. (PLRZ) Soars Over 20%: Key Levels and Potential ScenariosBollinger Squeeze - The Legal Advocate
Polyrizon Ltd Stock (PLRZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):